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Summary  
 
Gestational Trophoblastic Disease (GTD) is a rare complication of pregnancy that 
can develop into cancer. Medical outcomes are well researched but evidence is 
required on the impact of GTD on health-related quality of life (HRQoL) to 
improve care. The review was conducted to determine the impact of GTD and its 
treatment on HRQoL and identify how HRQoL is measured and appropriateness 
of these measures.  
 
Quantitative studies found HRQoL in long-term survivors to be at or above 
population norms. GTD appeared to have a negative impact on HRQoL where 
patients experience physical, psychological and social sequelae related to the 
condition. Clinically significant levels of anxiety, depression, sexual dysfunction 
and fertility-related distress were found. The results should be treated with 
caution because the evidence base was limited to small heterogeneous samples, 
retrospective data and the wide range of measures used. Within the qualitative 
data, new themes emerged including nerve damage, fatigue, amenorrhea, and 
grief. Currently, these areas are not captured in patient reported outcome 
measures (PROMs) and the content may not be valid for this population. Further 
qualitative research could lead to development of a GTD specific PROM providing 
reliable, meaningful and valid assessments and allowing longitudinal data to be 
obtained.  
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Background  
 
Gestational Trophoblastic Disease (GTD) is a rare condition that affects women 
during or after pregnancy. GTD is an umbrella term for a range of conditions, 
ranging from the pre-malignant disorders of complete molar (CM) or partial 
molar (PM) pregnancy, through to the malignant conditions commonly known as 
Gestational Trophoblastic Neoplasia (GTN), including invasive mole, 
choriocarcinoma, and the rare placental-site and epithelioid trophoblastic 
tumour (PSTT and ETT). 1,2 
 
All cases in the UK are registered for human chorionic gonadotropin (hCG) 
monitoring at one of three designated screening centres, and if subsequent 
treatment is required, patients are treated at one of the two Trophoblastic 
Disease Centres in Charing Cross Hospital, London, or Weston Park Hospital, 
Sheffield. The need for treatment is defined by malignant change and is almost 
always identified by a rising or plateau in serum hCG concentration, occurring in 
approximately 15% of CMs and 0.5-1% of PMs.2 
 
The GTD multi-disciplinary team (MDT) reflects a service that has moved away 
from a purely biomedical model of health towards patient centred care, 
supporting patients throughout their experience of GTD.3 Emotional support is 
paramount whilst patients are receiving monitoring and treatment, but 
outcomes are measured only in the medical domain including the assessment of 
hCG results, clinician assessed toxicity, nights in hospital, and cycles of 
treatment. The impact of the diagnosis and treatment on the patient’s quality of 
life is subjective and is not objectively or routinely captured at any stage. As a 
result all chemotherapy decisions are based wholly on historic data on medical 
outcomes. Without any medical need to assess the impact of treatment, 
communication and emotional support drop off sharply once active monitoring 
and treatment finishes.  
 
Health-related quality of life (HRQoL) is a multi-dimensional concept that 
represents a patient’s general perception of the effects of illness and treatment 
on physical, psychological and social aspects of life.4 HRQoL is a rapidly evolving 
field of research, and it is now generally accepted that the patients’ perspective is 
paramount in research and clinical practice.5,6,7 HRQoL outcomes can be 
captured using patient-reported outcome measures (PROMs).7 A PRO is a 
subjective outcome - referring to anything reported by ‘asking the patient’, or 
more formally defined as “any report of the status of a patient’s health condition 
that comes directly from the patient, without interpretation of the patient’s 
response by a clinician or anyone else”.4 A PRO comprises a variety of outcome 
measures such as emotional functioning (including anxiety and depression), 
physical functioning, social functioning, pain, fatigue, other symptoms and 
toxicity.  
 
Within the United Kingdom (UK) National Health Service (NHS) PROMs were 
introduced into routine health care in 2009, with the intention of extending 
routine measurement to a range of conditions including cancer. For policy 
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makers within the NHS, PROMs are an opportunity to move away from clinical 
outcome data that has centred on death and other clinical indicators such as 
infection rates, readmissions, recurrence, and adverse incidents.8   
 
Within NHS cancer services there has been a growth in overall PROM data. 
Whilst this has been mainly within clinical trials aiming to demonstrate the 
equivalence or benefit of novel cancer treatments, surgical oncology teams now 
commonly collect PROM data to inform clinical decision making and patient 
choice, regulate output and productivity, and inform commissioners on 
performance.8,9 Collecting and analysing PROM data for conditions that require 
lengthy treatments such as chemotherapy and radiotherapy can be challenging, 
as they involve complex packages of health and social care rather than a single 
intervention. As a result there is a difficulty in interpreting the resultant trends 
from PROMs and attributing any change to particular providers or 
interventions.8  
 
PROM data has proved useful in measuring the short and long-term effects of 
treatment for cancer patients having complex treatment and the HRQoL of 
survivors.10, 11 Current recommendations by the National Cancer Survivorship 
Initiative (NCSI), All Party Parliamentary Group on Cancer (APPGC) and 
Macmillan Cancer Support advocate the routine use of PROMs from diagnosis 
onwards, in order to help clinical teams focus on what really matters to patients, 
especially at the end of active treatment when patients often feel isolated and 
abandoned. 10, 12 Research supports this recommendation, providing strong 
evidence in cancer settings that well-implemented PROMs improve patient-
provider communication and patient satisfaction, in addition to growing 
evidence that PROMs improve monitoring of treatment response and the 
detection of unrecognised problems.13  
 
Justification for the Current Review 
 
Medical outcomes for GTD patients are widely researched and generally 
excellent, though a review of HRQoL in GTD is lacking. The aim of this systematic 
review is to evaluate all the existing evidence on the impact of GTD on HRQoL 
and identify gaps in the evidence. Currently there is no justification for using a 
particular PROM within GTD. This evidence may support the choice of a pre-
existing PROM in routine clinical practice or justify research in developing a GTD 
specific PROM to enable a more patient-focused service.  
 
Methods 
 
The systematic review was undertaken using the Cochrane group’s parallel 
synthesis approach,14 whereby qualitative evidence and quantitative evidence 
are conducted as separate, but linked, reviews. The qualitative synthesis can be 
used in parallel and juxtaposed alongside the quantitative synthesis in a process 
of data triangulation to aid in answering the review question.  
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Search Strategy and Selection criteria  
 
A comprehensive, systematic search of the following databases was conducted in 
July 2016: MEDLINE 1948- present via OVID plus In-process and other non-
indexed citations (all available years); Web of Science “All Databases”  “All 
Years”; PsycINFO 1806- present via OVIDSp In-process and other non-indexed 
citations; Cochrane Database of Systematic Reviews; PROMS bibliography 
(Oxford University). 
 
A combination of terms related to the population: ‘gestational trophoblastic’; 
‘molar pregnancy’; ‘hydatidiform mole’; ‘complete mole’; ‘partial mole’; 
‘choriocarcinoma’ ‘placental site trophoblastic’ and the intervention/outcomes: 
‘quality of life’; ‘sex*’; ‘anxiety’; ‘depression’; ‘psychosocial’; ‘psychologic*’; 
‘fertility’; ‘side effects’; ‘late effects’; ‘survivor’; ‘symptom*’ were employed using 
MeSH terms, free text searching and Boolean phrase capabilities.  
 
Exclusion Criteria: 
All other types of miscarriage not specified in the population criteria, e.g. all 
triploid pregnancies, ectopic pregnancies.  
Studies where the full text is not available in English.  
Studies that measure satisfaction with treatment or management strategies.  
 
Results  
 
The search retrieved 1400 articles with 17 quantitative and 4 qualitative studies 
included in the review. Study selection flow is shown in a PRISMA diagram 
(Figure 1). 
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Characteristics of Quantitative studies  
 
Population  
 
Of the 17 quantitative studies, eight included a mix of molar pregnancy (MP) and 
GTN patients, eight included only GTN patients and one included only MP 
patients. 12 of the 16 studies with GTN patients only included patients who were 
in complete remission.  In the remaining four studies active disease status was 
not explicit. Women were diagnosed with MP/GTN up to 30 years prior to 
enrollment. All the studies were cross-sectional. Within the GTN participants 
57% had single agent chemotherapy and 43% multi-agent chemotherapy.  
 
Figure 2a.     b. 
 
 
 
Number of Molar 
Pregnancy and GTN 
Patients
MP
GTN
Disease status of GTN/ MP 
patients 
Remission
Unknown
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Intervention – Instruments 
 
Thirty-one different instruments were identified. Seven studies developed a 
study specific questionnaire, or adapted a pre-existing questionnaire. Seven 
studies used standardised tools including generic to multi-dimensional 
questionnaires, disease specific questionnaires or instruments for specific 
aspects of HRQoL such as anxiety, depression, pain or fertility. 
 
See web appendix page 1 for Table I: Summary of PROMs used; and page 3 Table 
II: Summary of psychometric properties of validated PROMs in GTD 
 
Characteristics of Qualitative Studies 
 
The qualitative studies included 293 participants, 154 had GTD, 139 had GTN. All 
studies used an interpretive approach including qualitative data collection and 
data analysis.  
 
Table III: Summary of qualitative studies  
Study (reference) Study Setting Sample size Sample composition Data analysis 
Ngan & Tang (1986)38 Hong Kong 105 GTD & GTN NR 
Flam (1993)37 Sweden 22 GTN Thematic 
Petersen (2009)15 Australia 158 GTD & GTN NR 
Singh et al (2017)36 UK  8 GTN Framework 
NR: Not recorded  
 
Synthesis of Quantitative Evidence 
 
Molar Pregnancy (MP) 
 
This group included women diagnosed with a complete or partial molar 
pregnancy and undergoing screening at the time of the study, or had been 
screened in the past, for malignant change.  
 
Quality of Life 
 
Two studies 15,16 assessed overall quality of life, using a validated generic quality 
of life measurement tool (SWLS & WHOQOL-BREF). Although some of the 
participants may have not been on active follow up, these studies generated 
results from relatively homogeneous samples of MP patients who perceived their 
overall quality of life as good.  
 
Physical Functioning  
 
No study specifically explored the impact on physical functioning of a molar 
pregnancy. Ferreira et al, using the WHO QOL BREF,16 found HRQoL domain 
scores to be lowest for psychologic health 58·33 (95% CI 41·67-66·67) and 
highest for physical health 66·82 (SD 16·03) (a higher score indicating better 
HRQoL on a scale of 1-100).  
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Psychological Functioning  
 
Four studies used standardised measures of anxiety and depression (HADS, BDI, 
STAI trait/ state, CES-D) and suggest clinically significant levels of anxiety and 
moderate levels of depression in MP. 15-18 55% of women in Petersen’s study 
scored >8 on the HADS anxiety subscale  (>8 signifies presence of clinically 
significant anxiety/depression19) only 20% scored>8 on the depression 
subscale.15 The GTD related distress measured was higher amongst the MP 
group (p=0·022).17 The non-standardised tools, 20,21 also demonstrated moderate 
levels of anxiety, with more than 50% of MP patients feeling tense about their 
weekly hCG test. The causes of anxiety and depression were fear of future 
malignancy, uncertainties about future pregnancy and physical health.22 The 
results suggest similar levels of anxiety and depression across both MP and GTN 
groups, with evidence that anxiety is clinically significant.  
 
Social Functioning 
 
Relationship concerns and sexual function  
 
Five studies investigated the relationship between a MP patient and their 
partner, reporting a supportive, and often improved relationship. 15, 17, 20, 21,22 For 
both MP and GTN patients, there is evidence that not having a pregnancy 
following the diagnosis increases relationship dissatisfaction (p=0·01).17 
 
Sexual dysfunction was found to affect between 21% and 53% of MP patients, 
although the majority of women did not attribute the dysfunction to the MP.17, 22 
Sexual problems were reported as a lack of desire (42%) and stress (44%).22 The 
Sexual History Form-12 was used in one study and indicated mild sexual 
dysfunction, but the reasons for this were not explored.15  
 
Fertility concerns 
 
Women with MP and GTN have non-significant levels of infertility stress when 
measured by the validated Fertility Problem Inventory (FPI).18 However, 
significant differences in individual items on the score were found between 
younger and older women and for those with and without children.  
 
The non-standardised measures of fertility concern, which are more specific to 
GTD, appear to be contradictory. Some show MP patients are not overly worried 
about infertility, and acknowledge the likelihood of recurrence is minimal, with 
92% wanting to conceive again,21 and only 17% worried about a future 
pregnancy.20 However, Wenzel et al found 50·5% of MP patients fearing 
becoming pregnant again, and nearly 40% questioning their ability to have 
children. 22  
 
Gestational Trophoblastic Neoplasia (GTN)  
 
GTN, as a malignant condition, requires further treatment and women are 
assessed before chemotherapy using the FIGO 2000 scoring system.1 
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Chemotherapy can be single or multi-agent and lasts on average for 4-6 months.1 
A small number of malignant patients undergo surgery as part of their treatment.  
 
The GTN group is more diverse. No single study focuses on a particular FIGO 
score, type of treatment, or disease burden (metastasis/no metastasis) but 
gathers together a sample across the GTN spectrum.  
 
General HRQOL 
 
Seven of the studies,15, 16, 23-27 that include GTN patients measure HRQoL use a 
validated generic HRQoL tool (FACT-G, EORTC QLQ-C30, WHOQOL-BREF, SWLS, 
QoL-CS, SF 36 and the SF 12). Of these, there is a mixture of patients already in 
remission and patients undergoing active treatment. Where the study only 
includes patients in remission,24-27 the results show levels of HRQoL at or above 
population norms (Table IV).  
 
 
Table IV Summary of FACT-G scores from included studies and controls 
 Wilailak 
(2011)25  
Mean (SD) 
Gynaecology 
Cancer 
survivors 
Leenharattanarak 
(2014)26 
Mean (SD) 
GTN survivors 
Wilailak 
(2011)25 
Healthy 
controls 
General 
U.S Adult 
population 
norms28 
Physical Well 
Being 
24·19(3·90) 26·3 (1·84) 20·47(4·66) 22·7(5·4) 
Social Family 
Well Being 
19·68(5·28) 24·4 (4·76) 17·82 (5·62) 19·1(6·8) 
Emotional 
Well Being 
19·62(3·54) 21·2 (3·11) 17·25 (4·35) 19·9 (4·8) 
Function Well 
Being 
21·01(5·15) 26·2 (2·53) 19·36 (5·81) 18·5 (6·8) 
Overall FACT-
G 
82·15(12·86) 98·2 (8·98) 72·58(13·80) 80·1(18·1) 
 
 
Within FACT-G scores there were no significant differences based on population 
characteristics; however patients who desired further fertility showed 
significantly lower FACT-G score in the emotional well-being domain (p=0.02).26  
 
Studies including patients either in remission or during active treatment are 
undermined by a lack of information on disease status.15, 16, 23 Two studies using 
the EORTC-QLQ-C30 and the SWLS demonstrate that chemotherapy significantly 
reduces overall HRQoL.15, 23 The SWLS results show a lower overall score for 
chemotherapy patients versus non-chemotherapy patients (21·7 [95% CI 13·9-
29·6] vs. 25·0 [95% CI 18·2-31·9]).15 
 
In a study of women with gynaecological cancer, 38% of whom had GTN, the 
overall HRQoL score using the EORTC QLQ-C30 was 48.5,23 with the reference 
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score for female cancer patients using EORTC QLQ C-30 being 59.3.29 
Interestingly patients with metastasis reported significantly lower scores of 
HRQoL on the emotional (p<0·01), cognitive (p<0·01) and social functioning 
subscales, as well as significantly more severe scores of constipation (p<0·01) 
and financial impact items (p<0·01).23 
 
Utilising the WHO-QOL-BRE, Ferreira et al. included women needing 
chemotherapy (43%)(78% had single agent and 22% multi agent).16 The overall 
HRQoL was good, and chemotherapy exerted no significant influence on HRQoL. 
However, patients receiving chemotherapy had a higher physical and 
psychological burden and needed more social support compared to the MP 
group. It is unclear when the patients completed the questionnaire, which may 
undermine the results. 
 
Physical Functioning   
 
Only one study includes a tool specific to the physical domain, the Menopausal 
Symptom Checklist (MSC).30 This study includes only 5 GTN patients out of a 
sample of 88, but menopausal symptoms are an extremely common side effect of 
multi-agent chemotherapy.31 22-43% reported being very bothered by 
menopausal symptoms, most commonly vaginal dryness and hot flashes. 
 
Psychological Functioning  
 
Psychological HRQoL issues are the most extensively researched for GTN 
patients.15-18, 20, 22, 27, 30, 32 Four studies used a sample of GTN patients in complete 
remission,17, 20, 27, 30 while the others were a mixed sample between active 
treatment and complete remission.15, 16, 18, 22, 32 All studies included patients who 
had received either single or multi-agent treatment.  
 
GTN in complete remission 
 
The HADS, CES-D and IES-R validated tools showed no significant difference 
between MP and GTN, where across both groups 26% had elevated levels of 
anxiety (score> 8 on HADS-A), and 22% elevated levels of depression (score> 16 
on CES-D).17 Both these results exceed the 12-month local community rates of 
anxiety [17·9%] and depression [7·1%].17 Anxiety levels were higher among 
women without a pregnancy subsequent to the GTD diagnosis (p=0·04).17 For 
women who have impaired fertility post any cancer treatment, the CES-D and IES 
show clinically significant levels of distress (76%) and depression (26%).30  
 
GTN – mixed sample of unknown disease status 
 
This group of studies again showed no statistically significant differences in 
psychological outcomes based on the need for chemotherapy.15, 16, 18, 22 One study 
found a statistical difference (p<0·006) across several physical and emotional 
issues between those with metastatic and non-metastatic disease.21 
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General psychosocial outcomes and depression were assessed using the Mood 
Disturbance Scale and Psychosocial Response to Illness Scale and found 11% of 
the MP group vs. 16% in the GTN group experienced depression.22 Although 
anxiety was more prominent than depression in both groups (MP 21% and GTN 
24% anxiety).21 Two studies used the BDI and both found significant levels of 
depression within the GTN subgroup.16,18  
 
GTN patients with children had significantly better emotional functioning,15, 22, 30 
with significantly lower overall HADS scores attributable to a reduction in 
anxiety domains (HADS –A: children = 46.9%, no children =76%; p=0·04).15 The 
CES-D found women with children to have less overall depression, with 
significantly lower CES-D scores (P<0·047).30 In the psychosocial response to 
illness measure, women without children felt greater fear and a negative impact 
on self (p<0·02).22  
 
Social Functioning 
 
Relationship Concerns and Sexual Function 
 
The majority of patients felt well supported and their relationship to be 
unchanged or closer following GTN.17, 20, 22, 30, 33 However only one study used a 
validated measurement tool (Marital Satisfaction Survey - MSS).17 On a mixed 
sample of MP and GTN the MSS results were not significantly different across the 
two groups, showing overall satisfaction and support. However 26% reported a 
negative impact on their sex life.17 
 
Women with GTN reported a significant level of sexual dysfunction.15, 17, 20, 22, 27, 
30, 33 Three of the studies used validated tools and found sexual dysfunction 
compared to community controls using the Sexual History Form-12 (SHF-12), 
and the Female Sexual Functioning Index (FSFI) (Table VI). 15, 17, 30 Using the SHF-
12, participants scored a mean of 0·52 (95% CI 0·35-0·6) vs community control 
of 0·49.15 
 
Table V:  Summary of FSFI scores for GTN 
 Carter et al. (2009)30 
GTN patients – only 6% 
of sample 
Stafford et al. (2011)17 
GTN n=27 
FSFI mean (SD) 19·75 (9·83) 20·32(10·45) 
Lower score > sexual dysfunction; <26= dysfunction  
 
Sexual dysfunction is common amongst GTN patients using non-validated study 
specific questionnaires, though without any comparison to normative data.20, 22 
The most extensive investigation of sexual dysfunction in GTN explored 
symptoms of sexual dysfunction according to treatment type and prior to GTN.33 
Most women [94%] were sexually active with 90% satisfied with their sexual 
relations. However a majority reported at least one or more types of sexual 
dysfunction. The most common originated in the psychological state (70% 
absent or reduced desire, 65% frigidity), with less sexual disturbance of an 
organic or functional nature (52% vaginismus, 42% dyspareunia), although 53% 
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of patients reported these problems existed prior to diagnosis. 8% of those 
receiving single agent chemotherapy reported transitory dysfunction, with the 
highest level of dysfunction observed in those treated with multi-agent 
chemotherapy and surgery.33  
 
Fertility Concerns  
 
Fertility related distress appears to affect many women based on non-
standardised data; 38% were worried about the next pregnancy (88% feared 
another tumour),20 50% fear becoming pregnant,22 40% felt they had no control 
over their reproductive future,27 and 57% questioned their ability to have 
children.34 
 
The Fertility Problem Inventory (FPI) in a small sample was unable to detect a 
clinically significant level of global stress. 18 In a study focused on the impact of 
treatment-induced infertility, with a small sample of GTN cases (6%), most 
women (72%) reported clinically significant levels of distress related to their 
loss of fertility.30 
 
Synthesis of Qualitative Data  
 
The qualitative data was analysed to assess correlation with the quantitative 
data from the PROMs used in GTD in a process of data triangulation using the 
‘triangulation protocol’ technique.35 As described by O’Caithan et al, a 
convergence coding framework consisting of HRQoL subheadings was used to 
display the findings emerging from each separate review.35  
 
Physical Functioning  
 
Physical impact was most prevalent amongst GTN patients who underwent high 
dose chemotherapy, where a core theme was the reporting of problems 
persisting months and years after treatment.36, 37 These physical effects included 
peripheral neuropathy, hearing loss, breathing problems, fatigue affecting daily 
living, digestive problems and impaired concentration.  
 
Participants reported a chemotherapy-induced negative impact on body image, 
resulting from scars from treatment, weight gain and change in body shape 
following chemotherapy.36, 37 For those receiving single agent chemotherapy 
only, the majority found chemotherapy easier than expected.37 Amongst MP 
patients the data shows that women report physical complications, for example 
amenorrhea, are heightened by the impact of GTD.15  
 
Psychological Functioning 
 
The core themes were fear and anxiety, depression and self-esteem, with all four 
qualitative studies finding significant fear and anxiety relating to GTD.15, 36-38 
Fear experienced by MP and GTN patients is multi-faceted including recurrence 
of disease in a subsequent pregnancy, recurrence of the malignant tumour, fear 
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of dying, fear of not being able to achieve a successful pregnancy, fear of 
chemotherapy and permanent damage resulting from this.15, 36-38 
 
Participants in all four qualitative studies expressed feelings associated with a 
depressed mood, including: ‘sadness’, ‘upset’, ‘depressed’, ‘worthless’, ‘hopeless’, 
‘grief’. Many experienced sleep disturbance as a symptom of on-going 
depression.37 Women cite the main reason for depression as the loss of a child 
through the molar pregnancy.15, 37, 38 Reasons for low mood are the diagnosis 
itself which caused uncertainty and confusion, along with the delay to future 
childbearing.15, 37, 38 For ultra high risk patients who required inpatient 
treatment over many weeks, the most cited cause for depression was separation 
from their children.36 
 
Self-esteem was explored through questions about general outlook on life, and 
perceptions on their role as women. 33% of women felt that the disease had had 
a profound negative effect on their roles as women.37 This negative effect was 
seen in women who reacted most strongly to their pregnancy failure.37, 38 GTD 
impacted upon many women’s general outlook on life, with many feeling more 
irritated and sad, with a more pessimistic outlook than before the disease.37, 38 
Women also reported a change in outlook for the better as a result of GTD, where 
some women found their experiences had helped them find new priorities in life 
and given them a sense of the their own strength and ability to cope.36, 38 
 
Social Functioning 
          
Women found that one of the three most stressful aspects of GTN was the 
inability to communicate with family and friends due to the disease being 
unknown and uncommon.37 Participants felt they were ‘met with disbelief’ when 
they mentioned cancer and chemotherapy.37 The supportive role of partners, 
family, friends and specialist GTD teams was seen as very important to those 
having high dose chemotherapy, especially around ensuring the children were 
cared for in their absence.36  
 
The results around relationships are mixed, with an older study reporting 
minimal change in marital relationship (94% unchanged, 4% improved).38 
Partners who provided support were helpful and cited as a real source of 
strength.36 In a study from the Netherlands women reported they were left to 
cope with treatment on their own.37 In this study five couples separated due to 
the stress of coping with GTN, all of which were childless.37 In all studies MP and 
GTN had a negative impact on their sex life.15, 36-38 The majority of patients 
reported a decline in sexual activity.36-38 The reasons behind this decline were 
expressed as a loss of interest or sexual desire partly due to a fear of pregnancy. 
36  
Data Triangulation 
 
The core themes in the qualitative and quantitative data are well matched, but as 
would be expected, more detail emerges on the impact of GTD on HRQoL in the 
qualitative data. Within the overarching subheadings of physical, psychological 
and social functioning several new threads of data emerge.  
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Table VI: Overview of themes emerging from qualitative data 
Physical functioning Psychological 
Functioning 
Social functioning 
 Weight gain 
 Nerve damage 
 Hearing loss 
 Breathing problems 
 Fatigue that affected daily 
living 
 Digestive problems 
 Impaired concentration 
 Abnormal vaginal bleeding  
 Amenorrhoea 
 Body shape changes due to 
treatment 
 Sleep disorders  
 Grief 
 Fear of death 
 Resentment 
 Delay in childbearing 
 Isolation 
 
 
Discussion 
 
Whilst long-term survivors of GTD generally have a favourable HRQoL, there is 
evidence suggesting the condition is a major source of physical, psychological 
and social morbidity. The impact of GTD on physical functioning is rarely 
explored, but the effect is clearly linked with increased disease burden and more 
intensive chemotherapy. Due to the use of a variety of instruments meta-analysis 
was not possible; however clinically significant levels of anxiety are consistently 
found across the MP and GTN groups. Anxiety is most commonly associated with 
fertility concerns, but also regular blood hCG monitoring, fear of malignancy, 
recurrence and death. Depression is reported less frequently and is related to 
grief over the loss of an unborn child, and also anger and resentment at the delay 
in childbearing. Having a child is linked with lower levels of anxiety and 
depression for GTD patients, though levels of anxiety and depression are the 
highest for those desiring further fertility and not having a child subsequent to 
GTD. For the majority of women their relationship appears unchanged or closer, 
but many report a degree of sexual dysfunction primarily due to lack of desire 
and loss of interest in sex, although this may have been present prior to the 
diagnosis.  
 
The limitations of this analysis are that all of the studies are cross-sectional in 
design, providing only descriptive data at only one time-point with no 
longitudinal follow-up, and some studies use small heterogeneous samples. The 
patients include a mixture of GTD type, stage, treatment and time since diagnosis  
and utilise a range of different outcome tools . There are no studies explicitly 
investigating the short-term impact of GTD. Of the 19 studies evaluating GTN 
patients, 15 (79%) only included patients in remission who have had single or 
multi-agent chemotherapy and/or surgery, and months or years following 
diagnosis.  
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Of the tools used to measure HRQoL in GTD a significant proportion [22%] are 
non-validated and the remainder are a mixture of generic and condition specific 
measures with varying degrees of validity and reliability. No disease-specific tool 
has been developed in GTD, instead a patchwork of different measures has been 
used to try and accommodate the unique and varied set of domains that are 
considered relevant to GTD patients. No single PROM can be recommended for 
use within GTD patients as a result of this review.  
 
The scope of each instrument is reflected in the domains it covers, but it is 
difficult to assess the breadth and depth of their items, which vary from 
instrument to instrument and do not have equal weighting. As a result the use of 
these tools has several limitations in patients with GTD. For example, the EORTC 
QLQ-30 is broad in scope but does not address sexual function. The lack of any 
questions regarding fertility related distress, and the specific time frame of 
FACT-G (concerning the preceding seven days) does not allow the chronic, 
complex nature of the psychosocial sequelae of GTD to be expressed.  
 
The process of triangulation between quantitative and qualitative data highlights 
the gaps in the data found by the PROMs used in studies where several themes 
had not been identified in the quantitative review. The triangulation process is 
limited due by the small number of qualitative studies in GTD, and also the fact 
that these studies offer limited scope to be representative of a wider GTD 
population, due to sample composition and methodology. The gaps identified by 
the qualitative review show that the content validity of the PROMs used in these 
studies is compromised for GTD patients.  
 
Conclusion 
 
This review has created a parallel synthesis of PROM data in GTD patients and 
provides insight into the impact of GTD on HRQoL. The results suggest the 
presence of significant physical, psychological and social sequelae associated 
with GTD, with clinically significant levels of anxiety, depression, sexual 
dysfunction and fertility concerns observed. Although, for long-term survivors of 
GTD HRQoL outcomes are at or above population norms. The overall body of 
evidence is plagued by heterogeneity within the included studies and 
undermined by bias introduced due to long time intervals since diagnosis and 
the cross-sectional rather than longitudinal nature of studies. Despite there only 
being a small number of qualitative studies, data triangulation produced several 
new HRQoL themes suggesting that the existing PROMs do not demonstrate 
content validity for the GTD population. 
 
This review provides evidence of a need for a condition-specific PROM, enabling, 
monitoring an evaluating HRQoL issues associated with a GTD diagnosis in the 
context of supportive care provided by MDTs. As care pathways evolve, more 
evidence is needed on how to best allocate resources to support GTD patients 
during active monitoring, treatment and follow up based on prospective, 
longitudinal data, including the use of a condition-specific PROM that displays 
content and construct validity, reliability and responsiveness in the GTD 
population.  
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